Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL11058667 | 0.90 | MAPT (0.45) | CA12CA2CA3CA4CA6 | |
| SCHEMBL141927 | 0.87 | CA12 (0.69) | CA12CA2CA3CA4CA6 | |
| SCHEMBL3463478 | 0.87 | CA12 (0.69) | CA12CA2CA3CA4CA6 | |
| SCHEMBL3923590 | 0.87 | CA12 (0.69) | CA12CA2CA3CA4CA6 | |
| SCHEMBL7149888 | 0.87 | CA12 (0.69) | CA12CA2CA3CA4CA6 | |
| Hydrochloric Acid SCHEMBL7893135 | 0.85 | CA12 (0.65) | CA12CA2CA3CA4CA6 | |
| Dimethylaminoethanol SCHEMBL1132205 | 0.85 | — | — | |
| Formic Acid SCHEMBL2968613 | 0.82 | CA12 (0.47) | CA12CA2CA3CA4CA6 | |
| Dimethylaminoethanol SCHEMBL10604669 | 0.79 | MAPT (0.80) | CA12CA2CA3CA4CA6 | |
| SCHEMBL3194340 | 0.79 | MAPT (0.56) | CA12CA2CA3CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104292417-A | Hydroxyl terminated precursor and method of making the same | RENOSOL SYSTEMS LLC | 2015-01-21 | — | — | CN | disclosed |
| CN-101815736-B | Hydroxyl terminated precursor and method of making the same | RENOSOL SYSTEMS LLC | 2014-09-03 | — | — | CN | disclosed |
| US-8722753-B2 | Hydroxyl terminated precursor and method of making the same | LEAR CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-20100160593-A1 | ISOCYANATO TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME | LEAR CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-7678936-B2 | Isocyanato terminated precursor and method of making the same | LEAR CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2009026426-A1 | ISOCYANATO TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME | RENOSOL SYSTEMS, LLC (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054611-A1 | HYDROXYL TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME | LEAR CORPORATION | 2009-02-26 | — | — | US | disclosed |
| US-20090054604-A1 | ISOCYANATO TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME | LEAR CORPORATION | 2009-02-26 | — | — | US | disclosed |
| WO-2009026424-A1 | HYDROXYL TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME | RENOSOL SYSTEMS, LLC (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054604-A1 | ISOCYANATO TERMINATED PRECURSOR AND METHOD OF MAKING THE SAME | IDH3A, IDH2, CBR3 | CA12 162/4885CA2 471/4885CA3 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.